At Good Ancestors Policy, we have begun advocating for the adoption in Australia of various pandemic prevention and mitigation approaches. The residual uncertainty (specifically that we don’t have enough evidence to confidently advise on how that risk-benefit calculus should be assessed in different contexts) makes it very difficult currently to advocate for anything specific relating to far-UVC.
My hunch is that government-directed advocacy for far-UVC is only likely to be successful if we can say “this technology has significant benefits during a pandemic, but provides meaningful ongoing benefit from reducing ‘colds and flus’ even when there isn’t a pandemic”. That is, if the pitch is instead “install this technology, turn it on if a certain risk threshold is crossed, and the cost-benefit works out because pandemics are super bad” governments might be unlikely to bite even if that cost-benefit assessment is robust.
I agree. Getting more data on risks (safety) and real-world efficacy to formulate a more comprehensive and convincing cost-benefit calculus is probably the biggest priority for far-UVC right now.
Thanks Max—I’m glad this is a hot research topic.
At Good Ancestors Policy, we have begun advocating for the adoption in Australia of various pandemic prevention and mitigation approaches. The residual uncertainty (specifically that we don’t have enough evidence to confidently advise on how that risk-benefit calculus should be assessed in different contexts) makes it very difficult currently to advocate for anything specific relating to far-UVC.
My hunch is that government-directed advocacy for far-UVC is only likely to be successful if we can say “this technology has significant benefits during a pandemic, but provides meaningful ongoing benefit from reducing ‘colds and flus’ even when there isn’t a pandemic”. That is, if the pitch is instead “install this technology, turn it on if a certain risk threshold is crossed, and the cost-benefit works out because pandemics are super bad” governments might be unlikely to bite even if that cost-benefit assessment is robust.
Will keep following this closely!
I agree. Getting more data on risks (safety) and real-world efficacy to formulate a more comprehensive and convincing cost-benefit calculus is probably the biggest priority for far-UVC right now.